An experimental gene-editing therapy called VERVE-102 has shown promising results in an early clinical trial, reducing LDL (bad) cholesterol by 62% with a single dose in a small group of patients. The treatment, which uses mRNA-based gene-editing technology to modify liver cells, demonstrated sustained effects over 18 months with no serious adverse events reported. This breakthrough could potentially halve the risk of cardiovascular disease if the cholesterol reduction is maintained long-term.
Background
High cholesterol is a major risk factor for cardiovascular disease, and current treatments like statins require daily medication with potential side effects. Gene-editing therapies like VERVE-102 aim to provide long-term solutions with a single treatment by targeting the genetic basis of cholesterol regulation.
- Source
- Ars Technica
- Published
- May 28, 2026 at 09:39 PM
- Score
- 8.0 / 10